Health economic evaluation of an mRNA HR-HPV assay versus a DNA HR-HPV assay for the proposed French cervical screening programme
![](https://aquariusph.com/app/uploads/2021/07/france_770.jpg)
A health economic model to estimate the costs and benefits of an mRNA vs DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada
![](https://aquariusph.com/app/uploads/2021/07/toronto-770.jpg)
Evaluating the benefits and costs of using an mRNA versus DNA HR-HPV assay in the National Cervical Screening Programme in the Netherlands
![](https://aquariusph.com/app/uploads/2021/07/NL_770.jpg)
Modelling the impact of using a DNA compared to mRNA HPV assay as part of the cervical screening programmes in Sweden and Denmark
![](https://aquariusph.com/app/uploads/2021/07/Nordic_770.jpg)
Estimating the costs and benefits of HR-HPV assay choice in a theoretical HPV primary cervical screening algorithm in Ontario, Canada
![](https://aquariusph.com/app/uploads/2021/07/toronto-770.jpg)
Evaluating the choice of HPV assay in the French cervical screening programme with a decision tree model
![](https://aquariusph.com/app/uploads/2021/07/france_770.jpg)
Modelling the choice of high-risk human papillomavirus (HR-HPV) assay in the English cervical screening programme
![](https://aquariusph.com/app/uploads/2020/06/hpv-uk-770x225-1.png)